OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
March 4, 2026
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks so much, operator, and a good afternoon to each of you. We appreciate you being on the call for our results covering both the fourth quarter and the entire 2025 fiscal year. Slides have been prepared to go along with the remarks we'll make today, and you can find them in the Investors area of our site, omniab.com. Ahead of getting started, a quick reminder for those listening: anything OmniAb's management says on this call will contain forward-looking statements as defined under the federal securities laws; such forward-looking statements carry risks and uncertainties that might lead actual outcomes to differ materially from whatever results are anticipated. The cautionary statements in today's press release, along with our SEC filings, qualify these forward-looking statements. One important point: information shared on this conference call is time-sensitive and holds accuracy only as of the moment of today's live broadcast, which is March 4, 2026. Other than where the law demands it, OmniAb assumes no duty to revise or update any forward-looking statements so they reflect events or circumstances arising after today's call. With me this afternoon is Matt Foehr, who serves as OmniAb's President and CEO. Matt will walk through several business highlights, after which I'll take you through some financial details, and following that we'll open things up for your questions. So with that said, I'll hand things over to Matt.
Matt Foehr
executiveThank you, Kurt. Hello, everyone, and I appreciate you being on the call this afternoon. I'll begin on Slide #4 at this point. During 2025, our business generated some solid momentum, and we kept that going all year long. This was tied specifically to expanding our partner roster as well as the count of active programs that our technologies enable. As the year closed, we're pleased to share that we had 107 partners running 407 active programs. And as our pipeline of partners moves forward, certain later-stage programs are now coming into focus, carrying the potential to drive meaningful milestone revenue and build value over time, moving toward generating substantial future recurring royalty revenue streams; when it comes to innovation, we launched OmniUltra at the Antibody Engineering Conference in San Diego in mid-December. OmniUltra is the industry's first and only transgenic chicken platform to express ultra-long CDRH3 on a human antibody framework. We view OmniUltra as a significant new growth driver that can help us bring in additional partners, generate new program starts, create incremental near-term revenue opportunities and extend our reach into peptide focused discovery applications. In addition, we're establishing a solid foundation for our xPloration platform, which delivers our high-throughput single B-cell screening capabilities straight into our partners' labs. In our view, xPloration is very well positioned for significant growth with a growing pipeline of high-quality prospects and rising engagement as more partners actively assess the platform for use in their labs. And we anticipate xPloration will be additive to the business and will contribute to our growth. And I'd note that with growth in our partner base and our partner program portfolio, it's getting easier to point out that our differentiated platforms and business are highly scalable, letting us add new programs while keeping operating efficiency, which puts OmniAb on a sustainable path to future growth. And as Kurt will explain in his section shortly, we're on a trajectory to positive cash flow. Turning to our key business metrics, beginning on Slide #5. As I said, at year-end, we had 107 active partners, reflecting ongoing growth and diversification of our business from that standpoint. In Q4, we signed new license agreements with the Dana Farber Cancer Institute, Mabtrx Biosciences, which is a newly formed JV between Arrowmark Partners and Viking Global Investors, and with 2 global big pharma companies. The partner mix across discovery stage, commercials and academics keeps evolving and has stayed relatively constant percentage-wise. Most of our partners are headquartered here in the U.S; and the rest are mainly in Europe and in Asia; we keep broadening and diversifying our partner base, which I believe shows consistent strong execution by our business development and scientific teams. 2025 was a particularly strong year for us when it comes to partner additions. I'd also note that we're proud of how strong our partners are as well, which I think speaks volumes about the quality of our technologies. Eight among the world’s ten biggest pharmaceutical firms are OmniAb partners who are actively engaged; moving along to Slide #6, our metrics for active programs are displayed. We finished 2025 with 407 active programs, which amounted to a net gain of 44 programs over the course of the year. During 2025 we recorded 84 program additions, and a meaningful portion of those additions came from our more recent technology offerings. The count of additions we had in 2025 stood well above what we saw in recent years and exceeded 2024 by more than 20%; attrition, of course, is a natural and expected element of drug discovery and development. I should also point out that 40 programs were terminated during the year, which lines up with the usual ebb and flow we anticipate as partners tweak their portfolios, budgets, and technical priorities. Finally, and I believe this deserves emphasis, contracted future economics to OmniAb apply to over 98% of our active programs; for active antibody programs we hold more than $3 billion in total contracted milestone payments, with an average royalty rate of 3.4% across our portfolio. Slide 7 offers a different view of our active programs and illustrates the robust advancement activity observed throughout our partner pipeline during 2025. The figure on this slide encompasses our whole partner program pipeline; as the left side of this pyramid graphic makes clear, we added during the year those 84 new programs I mentioned a moment ago, which demonstrates the ongoing strength of our technology platforms. Once again, from that standpoint it was a very strong year and well above recent years. Regarding progression of active programs, 25 advancement or progression events occurred in 2025. 16 programs moved from discovery into preclinical development, reflecting our partners’ progress and the identification of promising therapeutic candidates to carry forward toward human trials. We also observed some healthy advancement deeper into the development process. 4 programs went from preclinical into Phase I clinical trials, and a couple of programs advanced into each of the clinical phases after that. Notably, 1 program arrived at the registration stage during 2025. Each advancement event appears on this slide, and I note that a couple of programs moved through more than one level or stage during the year. Turning to attrition, shown on the right side of this pyramid graphic, we had those 40 program terminations spread across various stages along with 4 program regression events during the year. Program regression is much less common, it should be said, but it does occur occasionally in a portfolio of active programs that has expanded to the size ours has in recent years. The attrition level shown here, in our view, matches the normal dynamics of drug development. What is especially encouraging and exciting are the 25 total program advancement events we saw as programs move from one development stage to the next. This trajectory shows that therapies built on OmniAb technology keep delivering solid results for our partners, both in development and in the clinic, and they're getting nearer to possible commercialization. That backs our opportunity for milestone and royalty revenue down the road and raises what each individual program is worth to our stakeholders. On Slide 8, you can see how post-discovery stage programs have grown across recent years; once more, I believe this illustrates the value our technologies deliver to our partners; and I'm aware of both the growth overall and the movement into the preclinical stage in recent years. Slide 9 presents the count of active clinical programs plus approved products, which came to 32 at the close of Q4; those figures are net of attrition and capture new clinical entrants along with attrition and a regression event that occurred during the year. In Q4, we marked a highly significant milestone as the first program derived from OmnidAb moved into human clinical testing. That program began human clinical trials in under 2 years from the point we launched the OmnidAb single domain discovery platform. So the fact that it produced a program reaching the clinic so quickly highlights both how much traction the technology has with our partners and its capacity to generate future value for our stakeholders. We expect the possibility of several new entries into clinical development for novel OmniAb-derived programs during this year, among them additional OmnidAb programs.
Matt Foehr
executiveWe're eager to see these ongoing clinical efforts keep moving forward—they still owe us more than $350 million in contracted milestones. Now moving to Slide 10. What we're doing here is showcasing and simply enumerating the partner pipeline programs in active clinical and commercial stages that remain active and bring residual downstream economics to OmniAb. Each program's position in this chart reflects whichever stage is furthest along in any region or condition. We've found this visual aid can really help investors tracking some of our better-known partner programs. Now shifting to Slide 11. I'd like to call out a handful of recent developments for partner programs that use our technologies. Immunovant keeps delivering what looks to us like solid headway and reports clinical momentum in the anti-FcRn field across numerous significant conditions with substantial unmet medical needs. Their next-gen candidate IMVT-1402 has a potentially registrational study in hard-to-treat rheumatoid arthritis that is now fully enrolled, with top line data anticipated during this year's second half. Top line data from our proof-of-concept study in lupus are likewise anticipated during this year's second half. IMVT-1402's development is advancing across numerous conditions with potentially registrational studies in Graves' disease, myasthenia gravis, CIDP and Sjögren's disease, all still on track, and with top line data for Graves' disease and myasthenia gravis anticipated in 2027. Immunovant also expect to share top line data from its 2 Phase III studies assessing batoclimab as a possible therapy for active moderate to severe thyroid eye disease during this year's first half. Additionally, Hanall reported ongoing preparation for an NDA submission in Japan for batoclimab as a therapy for myasthenia gravis. Moving over to the slide's center here. When the JPMorgan conference took place in January, Teva announced a funding agreement with Royalty Pharma worth up to $500 million to speed up clinical development of their anti-IL-15 antibody, TEV-'408, specifically for vitiligo. Top line results from the Phase 1b study in that condition are anticipated during this year's first half, and top line results of a Phase 2a study assessing 408 for celiac disease are anticipated during this year's second half; given recent developments and disclosures, this is an asset in a program that is rightly drawing more attention. Finally, Merck KGaA indicated that based on Phase I data, it intends to move M9140 straight into Phase III studies in metastatic colorectal cancer; this compound is a novel anti-CEACAM-5 antibody drug conjugate featuring a topoisomerase 1 inhibitor payload. It's been disclosed that the Phase III study is expected to begin during this year's first half, which represents a pretty significant acceleration of the program's development. On Slide #12, we present some of the upcoming events that I just referenced. 2026 is positioned to be a fantastic year for potential value-creating events. This calendar of near-term events is the strongest in recent memory. Beyond the data readouts and regulatory milestones we've already pointed to, we're anticipating fresh Phase I, Phase II, and Phase III study starts during this year as well. There will be more to share on that front as 2025 unfolds, though our initial take is that 2027 is likewise looking like a period with several significant events, among them certain programs I referenced on the slide just before this one. Now moving to Slide 13. I want to spend a moment on the 2 newest technology introductions from our company, which in our view set us up for considerable growth and demonstrate how dedicated we are to innovation — something we believe sets OmniAb apart in the eyes of our partners. OmniUltra stands as the first and only transgenic chicken to produce antibodies carrying ultra-long CDRH3, a structural trait normally seen in antibodies from cows. The design intent behind these ultra-long CDRH3 regions is to access binding pockets that remain out of reach for other antibodies or modalities, which could open the door to new therapeutic possibilities. The especially thrilling aspect of OmniUltra lies in what these ultra-long CDRH3 regions might make possible: entirely novel picobodies. At approximately 1/3 the size of a nanobody, picobodies rank as the smallest functional antibody fragment, and their potential applications are broad — from serving as building blocks for multispecifics, to acting as binders for CAR-T, to functioning as radiopharmaceutical therapies, and even as in vivo generated peptides. OmniUltra doesn't just broaden what we can do in antibody discovery; it also gives us a significant entry point into peptide therapeutics. As nearly everyone is aware at this point, peptide therapeutics have seen considerable growth along with industry attention and investment, largely propelled by how successful the GLP-1s have been across the last couple of years. Shifting to the panel on the right side of this slide. In May of last year, we introduced our xPloration partner access program. xPloration is our proprietary, innovative, high-throughput single B-cell screening platform, and it draws on machine learning along with artificial intelligence. Included in the xPloration platform are a competitively priced instrument plus proprietary single-use consumables, together with annual software subscriptions and maintenance contracts. Because of that, it holds potential for multiple revenue streams. Instruments already deployed are delivering outstanding performance for partners, and demand keeps coming in strongly for both on-site and virtual demos. Taken together, OmniUltra and xPloration serve as important new engines that widen our technology offering, grow our addressable markets, and bolster our competitive standing in the discovery platform space; and with that, I'll hand the call to Kurt so he can walk through our financial results. Kurt?
Kurt Gustafson
executiveThanks, Matt. I'll begin on Slide 15 by going over our revenue. For Q4 of 2025, total revenue came in at $8.4 million, versus $10.8 million during the comparable quarter of 2024. That drop was mainly the result of a reduction in license revenue, though a rise in milestone revenue offset part of it. Royalty revenue did go up, yet that stemmed from an adjustment made in the prior year period to reconcile royalties against actual product sales. We also recorded a modest contribution from xPloration during Q4. On Slide 16, you'll find our cost and operating expenses for the fourth quarter of 2025. As Matt noted, despite our expanding program portfolio, we have a scale platform that lets us stay highly disciplined about our cost structure. The chart makes clear that operating expenses fell to $24.1 million in Q4 from $26.7 million. Lower personnel costs accounted for most of that reduction, and we additionally saw reduced outside service costs, chiefly tied to less spending on our legacy small molecule ion channel programs. Q4 2025 also carried a noncash impairment charge of $3.9 million, mostly tied to certain small molecule ion channel property and equipment. Q4 2024 saw a comparable-sized write-off linked to intangibles. Now to Slide 17. I'll zero in on the lower portion of the P&L and offer just a handful of remarks. Look at the tax line: consistent with what we guided previously on taxes, we booked a full valuation allowance against the income tax benefit tied to our net loss, which explains why our effective tax rate sits near 0%. Our net loss in Q4 was $14.2 million, or $0.11 per share, against a net loss of $13.1 million, or $0.12 per share, in the same period a year earlier. On Slide 18, looking at the entire year 2025, revenue reached $18.7 million compared with $26.4 million in 2024. That gap came from decreases in both License revenue and Milestone revenue. Service revenue declined because certain small molecule ion channel programs wrapped up, and those drops were partly offset by roughly $800,000 of xPloration revenue stemming from the launch of our xPloration partner access program. Slide 19 covers our operating expense for the whole year. Operating expense dropped to $87.6 million in 2025 from $100.9 million a year ago. R&D expense for the year totaled $47.8 million, down from $55.1 million in 2024, on lower personnel costs, stock-based comp, and external expenses. As I noted for Q4 of 2025, there was also a noncash impairment charge of $3.9 million tied to legacy small molecule ion channel assets. G&A came to $29.2 million in 2025 versus $30.7 million in 2024, largely on lower legal fees and stock-based compensation. Now on Slide 20, which presents our P&L for the full year 2025 against 2024. Once again, I'll keep my attention on the bottom line. The net loss came to $64.8 million, which works out to $0.57 per share, versus a net loss of $62 million, or $0.61 per share, in 2024. If you back out the noncash impairment charge recorded in the fourth quarter, earnings per share for 2025 would have been $0.54. On Slide 21, you can find the company's P&L for the year, split out by quarter. As we've said before, and as this table makes clear, our revenue tends to be lumpy, since a large portion arrives through the achievement of Milestones, and one more thing worth noting here is that you'll observe a general downward trend in R&D and G&A expense, obviously setting aside the impairment charge from the fourth quarter. During 2025, we carried out workforce reductions affecting 22 employees, which generated savings in 2025 and will continue to do so going forward; Slide 22 presents the balance sheet as of December 31, 2025, and 2024. We closed out the year with $54 million in cash, cash equivalents and short-term investments. You'll also notice the usual reductions to goodwill and intangible assets; these intangible assets are tied to earlier corporate and technology acquisitions, which get amortized over time. Property, plant and equipment is lower as well, reflecting normal depreciation plus the noncash impairment charge from the fourth quarter. Slide 23 contains our financial guidance for 2026. The revenue guidance draws on information our partners have disclosed to us, along with what they've made public about their programs; taking that information together, we anticipate revenue for 2026 falling in the range of $25 million to $30 million. We anticipate operating expense landing between $80 million and $85 million as we keep realizing efficiencies in the business. Cash operating expense should come in somewhere between $50 million and $55 million. Our definition of cash operating expense is GAAP operating expense minus stock-based compensation, depreciation and the amortization of intangibles. Taken together, we expect those noncash items to total roughly $30 million in 2026; beyond that, the company anticipates finishing the year with a cash balance between $30 million and $35 million. And just like in 2025, the 2026 full year effective tax rate should be approximately 0% because of the valuation allowance. Now to Slide 24. Along with giving 2026 guidance, we wanted to share a few thoughts about our longer-term financial outlook. On the financial side, our business model is highly scalable. Looking ahead, we expect our revenue to shift from being more milestone driven toward being more royalty driven. That said, we hold over $3 billion of contracted milestones across our existing antibody programs, and $350 million of that relates to programs already in the clinic. Across our antibody portfolio, the average royalty comes to approximately 3.4%; revenue streams of this kind carry no corresponding cost of goods or selling costs. Another thing we've been doing lately is finding ways to trim what it costs us to operate. There's a dedicated group focused on business development whose job is to bring new partners on board, and the bulk of our spending on R&D goes toward keeping our animal colonies going, with only a modest portion aimed at developing new technology. That makes for a business with a lot of leverage potential. These charts make it clear that we've kept operating costs in check and will keep doing so, so we can capture the leverage our business model already has built in. Revenue should climb as the programs in our portfolio reach maturity. When you pair that with keeping a firm grip on operating expenses, the result is that our cash burn is going down, which sets us up to reach positive cash flow. With that said, I'd like to turn the call over to questions. Operator?
Puneet Souda
analystStarting with the partner programs. With the market backdrop and the fundraising that took place during the second half of last year and is still going on, and then on the clinical assets. I'm just curious whether you're noticing any impact from that? And what should our expectations be for growth in the new program this year, given how strong 2025 was for you? I realize it's always difficult to lay that out, but I'm just wondering how you're viewing new program growth for this year, and whether there's any feedback from the business element side?
Matt Foehr
executiveYes. Yes. Thank you, Puneet. It's Matt here. So yes, during 2025, we saw genuinely nice momentum when it came to program additions, and it was also a really strong year for partner adds. We picked up on a shift that started last year, as I think the industry began to get a bit more winded in sales. We saw partners, both those already with us and new ones, kicking off new programs. A lot of them are drawn to us thanks to our newer technologies. Some of the technologies we'd launched, namely OmnidAb, the year before, or the prospect of OmniUltra arriving, which we launched in mid-December. So we believe we're positioned very well for this year, coming on the tail-end of new technology launches, and we're clearly really pleased to see partners actively progressing, exploring accelerating development and that kind of thing. So we feel very good about that element as we look forward.
Puneet Souda
analystUnderstood. Then turning to xPloration, it's good to see revenue coming in from that. I'm not sure whether you're able to put a figure on it, though perhaps, for the whole — it would be great to hear if you've got a number in mind for the entire year. What kind of growth do you anticipate from that platform? It's a welcome revenue addition alongside the core animal models and programs, that program growth you're currently seeing. And I'm also curious whether you can share anything regarding the pull-through aspect of xPloration.
Matt Foehr
executiveSure, Puneet, let me offer a bit of color on that. As you know, we brought xPloration to market midway through last year alongside our partner access program, which we showcased at the PEGS conference, and we sold one instrument shortly thereafter; clearly, the instruments now in the field are delivering excellent results for partners. xPloration clearly holds the potential to bring in revenue through multiple routes, not just instrument sales, but also the single-use consumables, which carry a quite attractive high margin, plus subscriptions and maintenance contracts. Interest has been flowing in very strongly. It involves what I'd describe as our top-tier partners, the ones clearly engaged in substantial discovery work, and I believe they're drawn to xPloration owing to its throughput and ease of use, being able to perform multiple runs within a day and to produce enormous volumes of data, which I think is very well timed given certain interests within the industry; so yes, we do anticipate it will contribute this year. That's something we're excited about. We haven't broken out the individual components of revenue guidance, but we do foresee substantial growth for xPloration and a contribution this year.
Michael King
analystTo start, it's good to see that you're light on cattle and that costs are being kept in check. However, when it comes to measuring valuation, it appears to me that what matters more is that you're bringing in new programs and pushing initiatives forward within the pipeline. So I'm curious: how untouchable is the goal of cash flow neutrality or positivity when weighed against further investments you may wish to pursue in order to create more partnerships?
Matt Foehr
executiveYeah, yeah, Mike, that's a fair question. What I'd say is that we're clearly creating this company so that it stands apart when it comes to the technologies we recognize the sector requires, correct? Yet doing so in a highly efficient manner that delivers value to our shareholders and our stakeholders. We occupy what I'd describe as a rather enviable and one-of-a-kind spot within the sector, correct, with 107 partners. More than 407 programs that those partners are moving along through different phases of development provide us with an extremely useful vantage point on the sector, correct? We're able to see — we grasp which targets matter most to the largest and most valuable pharmaceutical firms globally, correct? And that shapes, in a sense, the way we put money into our technologies, it shapes, in a sense, the tasks we carry out and the manner in which we collaborate with those partners. And I believe you're witnessing the payoff from that across a number of our metrics, correct? So when it comes to bringing on additional partnerships, we're able to accomplish that fairly efficiently within the framework we operate. We speak often about the innovations we opt to fund, and we do so armed with an understanding not just of where the sector stands today regarding discovery and innovation, but also of where it is going, correct? And that is what shaped our spending in prior years and items such as our Omni dab single domain technology. And then, more lately, with OmniUltra arriving in December, which is — it sounds <<inaudible>> yet it's a chicken that produces cow-like antibodies featuring fully human sequences. That was a case where — we recognized demand would exist for it, drawing on our conversations with partners. So from our standpoint, I believe we're able to do this very efficiently. We believe that serves all of our stakeholders, and that's the area we will keep concentrating on.
Michael King
analystAll right, and now a very brief follow-up. Turning to the number of shares in Q3 and Q4, what's behind that?
Kurt Gustafson
executiveYeah, thanks Mike. We brought in additional funds, and because of that capital raise, our share count went up over that stretch.
Matt Hewitt
analystPerhaps we could go a bit deeper regarding the xPloration chance. You seem to be witnessing robust demand. How many systems had been installed or rolled out as we closed out the prior year? And with the pipeline in mind, what might that reach during '26?
Matt Foehr
executiveYeah, yeah. Thank you, Matt. Yeah. So to address the first portion quickly: 2, instruments were deployed by the close of 2025; and turning to the current year, like I mentioned, we anticipate xPloration will grow, and we are thrilled by the stream of interest coming from our top-tier partners. For lots of these businesses, these are clearly bigger capital outlays. That means sales cycles may run longer, something we completely anticipated at the time we introduced the technology. So they must clear budget and capital approval processes, and so on. Still, the response has been very encouraging. It keeps our crew extremely occupied, which is wonderful, and the appetite for demos along with how those demos have performed has truly been outstanding. So with luck, that provides the insight you were after.
Matt Hewitt
analystYeah, no, that's excellent. Then you brought up — Kurt, I believe you touched on this briefly in your prepared remarks regarding your path to cash flow breakeven, considering the pipeline, and Matt, you mentioned it too, with the pipeline of opportunity, things moving through the channel, or through the clinic rather, this year and into next year, when do you think you could reach breakeven? Do you see that potentially happening as you exit '27, or perhaps a bit further out? I'm just trying to get a sense of the timeline for when you might get to that level?
Matt Foehr
executiveYes. Thanks, Matt. Great question. A big chunk of the money we'll bring in down the road depends on how far our partners push their programs through trials and the approval process. And even though we won't put a specific date on when we hit breakeven, the fact that these partner programs keep expanding and moving into later stages makes us feel sure we're headed the right way — that the course we're on can get us to that point. In other words, we can see it approaching, yet we're unable to hand you a firm date at this moment, though it is definitely approaching.
Joe Pantginis
analystTurning to xPloration, the upside is clear to all of us. I'm just wondering how you'd frame it — from what I heard, it seems 2 units went out in '25. Yet as we look ahead, what about the manufacturing demands and the money you'll need to put in, plus how that hits operating costs once the program scales up.
Kurt Gustafson
executiveYeah, Joe, that's a fair question; this instrument is something we rely on for in-house studies. We've got a group of people who know the device and work with it constantly. That means we don't have to bring on a big extra crew to pull this off. We've opened this program up to our collaborators. Typically, units get assembled more or less tailored, so to speak, or made for these parties once an order comes in. That also means we don't face a significant outlay for stockpiling, so to speak, in order to make it happen. At this point we're running it very tight, since we want to be certain this adds value to the company to the greatest degree we can achieve down the road.
Chad Wiatrowski
analystChad here, filling in for Brendan. Let's start with Ultra. What's the early feedback been like from partners? And are you starting to see the demand ramp you mentioned last quarter?
Matt Foehr
executiveMatthew, thanks, Chad. Ultra's launch is going really well. The reception has made me quite happy. Of course, we're still in the very early stages. It only came out in mid-December. But before releasing it, we did an enormous amount of validation work on Ultra. The talks given at the AET Conference in December pointed to a wide range of therapeutic targets we'd evaluated when we launched. We also had 3 partner programs already moving forward at that point. That figure has grown, and we anticipate it will keep growing. So the engagement we're seeing is quite strong. The technology is doing very well. As a result, we're feeling quite confident about its future effect on the business.
Chad Wiatrowski
analystThat's great. Do you notice any particular pull in other modalities that you'd point to as interesting?
Matt Foehr
executiveYeah. I'd say the industry has broadly been moving toward, as I put it, smaller is better, with a search for tinier binding units, so to speak, that can be linked together into multispecifics. Clearly, radio pharma has become a significantly expanding opportunity. That's a development the industry has noticed. And beyond that, we've unlocked entirely fresh possibilities and an altogether different call file when it comes to peptides, correct? So peptides represent a field of rising and mounting interest. There's considerable expansion there, and it has truly broadened what you might call our call file to well over 130 companies that are new potential targets for us. So taking all of that together, I'd say we're enthusiastic about it. Once again, it's early days, yet we're generating some solid momentum and we're enthusiastic about it.
Chad Wiatrowski
analystAbsolutely. I'll play that role. I'm — bringing in one more question here. But regarding your fiscal year '26 revenue guidance, it's somewhat suggesting a bounce back to 2024 levels. Could we safely say that you're noticing initial indicators of a market recovery? And how much visibility do you actually have regarding your partners' spending expectations, which served as the basis for that outlook?
Kurt Gustafson
executiveYes. I believe a large portion of — a significant share of our revenue comes from milestones. And as we've discussed on a quarterly basis, the revenue figure is uneven; that's true across years too. So it's essentially just a result of which clinical or regulatory events will occur; and as we look ahead toward 2026 according to what partners have communicated, we estimate what those milestones could be. And so I'm not certain it's truly whether the industry or the broader market is what's pushing that, as much as us examining the highly specific events occurring with the programs we have. Any events that are emerging for 2026. That's genuinely the main thing behind it.
Srikripa Devarakonda
analystAnna here, covering for Kripa. I'd like to ask something regarding xPloration. Could you share a qualitative picture of how interest in xPloration is shaping up — is it arriving via new partners, or does it lean more toward going deeper with the partner we already have?
Matt Foehr
executiveYes, excellent question. Both, really. As I noted, when it comes to the partners we already work with, those with obvious quick engagers who are looking at xPloration with serious interest have been our top-tier partners, correct? This group consists of researchers heavily involved in antibody discovery who want access to larger datasets, and they find the instrument's throughput and user-friendly design appealing. It's also attracting new parties—ones who aren't yet working with our repertoire generation discovery platform. That ties back to something I mentioned earlier when I talk about what xPloration brings to the table for the company. Beyond strengthening ties with the partners we already have and putting frameworks in place that let us generate value sooner — whether that's during a product's development, a program's rollout, or the partnership itself — it also draws in new players whom we can onboard as wider-ranging collaborators along the way. So that's yet another upside of xPloration.
Analyst
analystFantastic; and regarding OmniUltra, is there anything we ought to anticipate as milestones for OmniUltra during 2026?
Matt Foehr
executiveIndeed. Clearly, I anticipate that we'll keep bringing on additional partners and programs involving OmniUltra. That will be our primary emphasis when we roll out the technology. Once those programs, as is clear, move through development and advance into later phases of development, we anticipate that will occur when the time is right, but what comes first will be generating fresh partnerships and fresh programs and utilizing the technology in that manner.
Stephen Willey
analystI wanted to ask about a footnote on Slide 24. My understanding is that for programs with royalty tiers, you're applying some sort of sales assumption and calculating a blended royalty. Have you disclosed, or could you tell us, how many of the active programs use a tiered structure versus a fixed one?
Kurt Gustafson
executiveGood question, Steve. I don't believe that figure has been shared previously. It's above a handful, though I wouldn't characterize it as most of them. I'm not sure, Matt...
Matt Foehr
executiveYeah, there are definitely quite a few that use tiers — but for most of the deals we do, the royalties stay flat. You'll run into cases where tiers come into play, sure, though what we see most often is just one straight royalty rate.
Stephen Willey
analystUnderstood. Then I'm also wondering, where do you see that average royalty rate — I believe it's 3.4% — heading over time, and are you aiming to secure a larger royalty on certain newer technology products such as OmnidAb and OmniUltra?
Matt Foehr
executiveYeah. For Discovery Technologies, Steve, there's always that question of how hard you can press on royalties. Clearly, greater innovation lets us generate stronger economics overall, though those economics may involve a mix of upfront payments, service payments, and milestones paid over time alongside royalty; so in many cases it truly hinges on the negotiation dynamics, the soft points or the interests of the partner. That said, I'd note that technologies with more innovation do create greater value for our shareholders. And that's among the reasons we've introduced new technologies such as OmniUltra and OmnidAb, but hopefully that provides a bit of insight into how this works.
Matt Foehr
executiveExcellent. Thank you. I want to express appreciation to all of you for being on today's call, and for the questions and involvement; we're looking forward to talking about our Q1 financial results in a few months' time. In the interim, we will be taking part in the Leerink Global Healthcare Conference, happening next week in Miami. So hopefully some of you will be there. We also anticipate being out on the road, probably in the spring, doing NDRs and similar things. So once more, thank you, and enjoy the rest of your day.
Operator
operatorEveryone, that wraps up today's call. We appreciate all of you joining us. At this point, you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.